Merck Serono to Present at GTCbio`s 2nd Assay Development and High Throughput Screening Conference (May 31-June 1, Boston, MA)
Released on = May 3, 2007, 3:56 pm
Press Release Author = GTCbio
Industry = Pharmaceuticals
Press Release Summary = Dr. Dominique Perrin, Group Leader of Biochemical Pharmacology at Merck Serono International in Switzerland will give a presentation entitled “Phosphatases Inhibitors: from Screening to Biological Activities” at GTCbio’s 2nd Assay Development & High Throughput Screening Conference on May 31-June 1 in Boston, MA.
Press Release Body = Dr. Dominique Perrin, Group Leader of Biochemical Pharmacology at Merck Serono International in Switzerland will give a presentation entitled “Phosphatases Inhibitors: from Screening to Biological Activities” at GTCbio’s 2nd Assay Development & High Throughput Screening Conference on May 31-June 1 in Boston, MA.
Protein tyrosine phosphatases (PTPs) play key roles in regulating tyrosine phosphorylation levels in cells. Since the discovery of PTP1B as a major drug target for diabetes and obesity, PTPs have emerged as a new and promising class of signaling targets for drug development in a variety of therapeutic areas. Phosphatase screening in-house was based either on generic substrate 6,8-difluoro-4-methyumbelliferyl phosphate (DiFMUP) using fluorescence intensity readout or on specific phosphopeptides using an off-chip mobility shift assay. Whilst assay robustness and sensitivity were comparable for both assays, the mobility shift assay required a longer development time due to identification and synthesis of a specific peptide and its cost per data point was higher. However whilst most scaffolds found with DiFMUP assay were confirmed in the mobility shift format, this latter assay allowed the identification of novel, more drug-like chemical scaffolds. Outcomes of screening campaigns as well as biological activities of positives will be presented.
GTCbio’s 2nd Assay Development & High Throughput Screening Conference on May 31-June 1 will take place at the Omni Parker House in downtown Boston, MA. The meeting will be held concurrently with GTCbio’s 2nd Protein Kinases in Drug Discovery Conference.
For more information including a detailed agenda, exhibitor opportunities and registration information visit http://www.gtcbio.com/conference/conferenceDetails.aspx?id
Web Site = http://www.gtcbio.com
Contact Details = GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
2012
